Crossmark

Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study)

Crossref DOI link: https://doi.org/10.1007/s00384-018-2979-9

Published Online: 2018-02-27

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kosugi, Chihiro https://orcid.org/0000-0003-3719-6425
Koda, Keiji

Ishibashi, Keiichiro

Yoshimatsu, Kazuhiko

Tanaka, Soichi

Kato, Ryouji

Kato, Hiroyuki

Oya, Masatoshi

Narushima, Kazuo

Mori, Mikito

Shuto, Kiyohiko

Ishida, Hideyuki
License Information

Text and Data Mining valid from 2018-02-27
More Information

Article History

Accepted: 7 February 2018

First Online: 27 February 2018

Compliance with ethical standards

:

: The authors declare that they have no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/or research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.